Market Summary
USD27.55+0.11
Delayedas of 27 Sep 2023, 02:48 pm0.40%
SDGR Alerts
SDGR Stock Price
SDGR RSI Chart
SDGR Valuation
SDGR Price/Sales (Trailing)
SDGR Profitability
SDGR Fundamentals
SDGR Revenue
SDGR Earnings
Price Action
52 Week Range
15.8559.24
(Low)(High)
Last 7 days
-12.0%
Last 30 days
-21.9%
Last 90 days
-38.7%
Trailing 12 Months
14.6%
SDGR Financial Health
SDGR Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SDGR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Herman Jenny | acquired | 5,454 | 1.2 | 4,545 | svp & controller |
2023-08-09 | Dugan Margaret | acquired | - | - | 15,000 | chief medical officer |
2023-08-09 | Lorton Kenneth Patrick | sold | -400,642 | 40.0642 | -10,000 | evp & chief technology officer |
2023-06-30 | Tran Yvonne | sold | -602,000 | 50.00 | -12,040 | evp, clo & cpo |
2023-06-30 | Tran Yvonne | acquired | 204,680 | 17.00 | 12,040 | evp, clo & cpo |
2023-06-15 | OBEROI ARUN | acquired | - | - | 6,250 | - |
2023-06-15 | Friesner Richard | acquired | - | - | 6,250 | - |
2023-06-15 | Kapeller-Libermann Rosana | acquired | - | - | 6,250 | - |
2023-06-15 | Lynton Michael | acquired | - | - | 6,250 | - |
2023-06-15 | Sender Gary | acquired | - | - | 6,250 | - |
Which funds bought or sold SDGR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 2.34 | 984,000 | 2,031,000 | -% |
2023-09-13 | CGC Financial Services, LLC | new | - | 210,712 | 210,712 | 0.14% |
2023-08-23 | WOLVERINE TRADING, LLC | reduced | -78.48 | -579,588 | 399,412 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4,110 | 3,086,520 | 3,125,710 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.31 | 1,612,980 | 3,505,680 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | new | - | 889,000 | 889,000 | 0.01% |
2023-08-18 | Legato Capital Management LLC | new | - | 258,086 | 258,086 | 0.04% |
2023-08-16 | Nuveen Asset Management, LLC | added | 9.46 | 3,817,490 | 7,368,490 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 23.1 | 2,186,660 | 3,826,070 | -% |
2023-08-15 | Parkside Financial Bank & Trust | added | 7.00 | 2,709 | 5,342 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
SDGR Alerts
Schedule 13G FIlings of Schrodinger
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 10, 2023 | vanguard group inc | 10.69% | 6,669,820 | SC 13G/A | |
| Jul 07, 2023 | blackrock inc. | 13.5% | 8,438,927 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.25% | 5,120,349 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 6.4% | 3,956,805 | SC 13G | |
| Feb 09, 2022 | blackrock inc. | 5.0% | 3,057,148 | SC 13G/A | |
| Feb 04, 2022 | blackrock inc. | 5.1% | 3,123,673 | SC 13G | |
| Dec 01, 2021 | shaw david e | 3.9% | 2,401,777 | SC 13G/A | |
| Apr 26, 2021 | shaw david e | 17.2% | 9,662,606 | SC 13G/A | |
| Feb 12, 2021 | bill & melinda gates foundation trust | 23.2% | 16,145,857 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 6.76% | 3,805,264 | SC 13G |
Recent SEC filings of Schrodinger
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 03, 2023 | 8-K/A | Current Report | |
| Aug 03, 2023 | 3 | Insider Trading | |
| Aug 02, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 10-Q | Quarterly Report | |
| Jul 10, 2023 | SC 13G/A | Major Ownership Report | |
| Jul 07, 2023 | SC 13G/A | Major Ownership Report |
Peers (Alternatives to Schrodinger)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABT | 167.5B | 40.2B | -7.66% | -3.16% | 32.45 | 4.16 | -11.68% | -39.67% |
IDXX | 35.9B | 3.5B | -12.23% | 30.55% | 45.38 | 10.22 | 6.21% | 19.20% |
VEEV | 31.9B | 2.2B | 5.42% | 26.20% | 59.01 | 14.28 | 11.56% | 37.20% |
| MID-CAP | ||||||||
INSP | 5.5B | 526.1M | -13.07% | 8.40% | -133.78 | 10.44 | 74.86% | 6.49% |
LNTH | 4.6B | 1.1B | -1.66% | -2.00% | 136.43 | 4.05 | 69.36% | 3.03% |
TDOC | 3.1B | 2.5B | -13.70% | -28.01% | -0.78 | 1.24 | 13.30% | 59.30% |
OMCL | 2.1B | 1.2B | -21.26% | -46.64% | -88.88 | 1.67 | -1.77% | -138.27% |
QDEL | - | - | -8.05% | -1.80% | - | - | - | - |
| SMALL-CAP | ||||||||
SDGR | 2.0B | 193.8M | -21.93% | 14.57% | 29.63 | 10.14 | 18.78% | 144.88% |
TRHC | 278.7M | 338.1M | 0.29% | 140.65% | -2.92 | 0.82 | 22.28% | 17.91% |
ICAD | 51.8M | 24.5M | -0.49% | 0.49% | -4.14 | 2.11 | -24.11% | 3.57% |
HTGM | 1.3M | 6.2M | -81.65% | 3.23% | -0.06 | 0.21 | -28.21% | -7.22% |
Schrodinger News
Returns for SDGR
Cumulative Returns on SDGR
-17.7%
3-Year Cumulative Returns
Risks for SDGR
What is the probability of a big loss on SDGR?
97.4%
Probability that Schrodinger stock will be more than 20% underwater in next one year
84.8%
Probability that Schrodinger stock will be more than 30% underwater in next one year.
83.8%
Probability that Schrodinger stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SDGR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Schrodinger was unfortunately bought at previous high price.
Drawdowns
Financials for Schrodinger
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Revenue | -1.7% | 193,794,000 | 197,074,000 | 180,955,000 | 170,282,000 | 163,152,000 | 154,467,000 | 137,931,000 | 124,793,000 | 120,740,000 | 114,048,000 | 108,095,000 | 100,895,000 | 95,058,000 | 90,976,000 | 85,543,000 | 79,614,667 | 79,502,000 | 82,964,000 |
| Gross Profit | -2.8% | 115,408,000 | 118,732,000 | 101,022,000 | 88,679,000 | 82,593,000 | 77,439,000 | 65,620,000 | 58,251,000 | 62,408,000 | 64,011,000 | 63,472,000 | 60,007,000 | 55,446,000 | 51,714,000 | 49,093,000 | 44,754,667 | 45,710,000 | 52,016,000 |
| Operating Expenses | 5.4% | 281,743,000 | 267,407,000 | 247,839,000 | 229,473,000 | 211,898,000 | 193,613,000 | 177,063,000 | 163,763,000 | 148,691,000 | 137,039,000 | 124,388,000 | 112,186,000 | 103,472,000 | 96,616,000 | 87,808,000 | 85,912,000 | 84,862,000 | 74,468,000 |
| S&GA Expenses | 4.8% | 34,710,000 | 33,116,000 | 30,642,000 | 27,235,000 | 25,630,000 | 23,582,000 | 22,150,000 | 20,850,000 | 19,263,000 | 18,245,000 | 17,795,000 | 18,863,000 | 20,079,000 | 21,060,000 | 21,364,000 | 20,828,000 | 20,872,000 | 20,372,000 |
| R&D Expenses | 8.3% | 150,873,000 | 139,291,000 | 126,372,000 | 116,975,000 | 107,309,000 | 97,278,000 | 90,904,000 | 83,078,000 | 76,878,000 | 72,443,000 | 64,695,000 | 58,458,000 | 51,792,000 | 44,666,000 | 39,404,000 | 37,762,667 | 35,938,000 | 33,752,000 |
| EBITDA | -100.0% | - | 45,983,000 | -144,782,000 | -148,369,000 | -144,248,000 | -131,909,000 | -97,961,000 | -78,523,000 | -39,948,000 | -8,893,000 | -22,634,000 | -18,574,333 | -34,058,000 | -30,842,000 | -22,332,000 | - | - | - |
| EBITDA Margin | -100.0% | - | 0.23 | -0.80 | -0.87 | -0.88 | -0.85 | -0.71 | -0.63 | -0.33 | -0.08 | -0.21 | -0.18 | -0.36 | -0.34 | -0.26 | - | - | - |
| Earnings Before Taxes | 77.1% | 72,336,000 | 40,836,000 | -149,126,000 | -152,224,000 | -147,577,000 | -134,827,000 | -100,808,000 | -81,728,000 | -43,462,000 | -12,561,000 | -26,292,000 | -22,105,000 | -37,574,000 | -34,350,000 | -25,972,000 | -25,064,000 | -13,160,000 | -23,208,000 |
| EBT Margin | -100.0% | - | 0.21 | -0.82 | -0.89 | -0.90 | -0.87 | -0.73 | -0.65 | -0.36 | -0.11 | -0.24 | -0.22 | -0.40 | -0.38 | -0.30 | -0.31 | -0.17 | -0.28 |
| Net Income | 361.1% | 66,354,000 | 14,390,000 | -149,186,000 | -152,692,000 | -147,846,000 | -135,130,000 | -100,393,000 | -81,639,000 | -42,780,000 | -11,876,000 | -24,463,000 | -21,254,000 | -36,614,000 | -33,275,000 | -24,571,000 | -24,110,666 | -13,150,000 | -23,392,000 |
| Net Income Margin | -100.0% | - | 0.07 | -0.82 | -0.90 | -0.91 | -0.87 | -0.73 | -0.65 | -0.35 | -0.09 | -0.23 | -0.20 | -0.37 | -0.36 | -0.29 | -0.30 | -0.16 | -0.28 |
| Free Cashflow | 100.0% | - | -120,964,000 | -127,697,000 | -122,104,000 | -102,164,000 | -107,820,000 | -77,836,000 | -14,409,000 | -13,345,000 | 9,406,000 | 14,219,000 | -39,935,000 | -33,795,000 | -28,828,000 | -27,895,000 | -21,964,000 | -20,512,000 | -22,752,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Assets | 0.3% | 842 | 839 | 689 | 662 | 688 | 720 | 756 | 763 | 717 | 744 | 746 | 680 | 350 | 350 | 155 |
| Current Assets | -1.9% | 592 | 604 | 534 | 524 | 557 | 586 | 625 | 622 | 650 | 675 | 683 | 621 | 307 | 313 | 119 |
| Cash Equivalents | 22.6% | 286 | 233 | 90.00 | 103 | 131 | 121 | 123 | 164 | 121 | 134 | 203 | 211 | 111 | 145 | 26.00 |
| Net PPE | 23.4% | 20.00 | 16.00 | 14.00 | 14.00 | 12.00 | 11.00 | 10.00 | 9.00 | 7.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 |
| Goodwill | 0% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - |
| Liabilities | -7.3% | 230 | 249 | 241 | 199 | 195 | 189 | 199 | 183 | 112 | 112 | 122 | 49.00 | 53.00 | 54.00 | 57.00 |
| Current Liabilities | -13.5% | 107 | 123 | 109 | 89.00 | 86.00 | 86.00 | 91.00 | 73.00 | 70.00 | 68.00 | 73.00 | 39.00 | 43.00 | 42.00 | 45.00 |
| Shareholder's Equity | 3.6% | 611 | 590 | 448 | 463 | 493 | 531 | 557 | 580 | 606 | 632 | 624 | 631 | 296 | 296 | - |
| Retained Earnings | 1.7% | -245 | -250 | -379 | -351 | -312 | -264 | -229 | -199 | -164 | -129 | -129 | -118 | -122 | -118 | -105 |
| Additional Paid-In Capital | 2.0% | 857 | 840 | 829 | 818 | 808 | 797 | 787 | 778 | 769 | 761 | 753 | 748 | 417 | 414 | 12.00 |
| Shares Outstanding | 0.2% | 72.00 | 71.00 | 62.00 | 71.00 | 71.00 | 71.00 | 62.00 | 71.00 | 71.00 | 70.00 | 61.00 | 66.00 | 63.00 | 41.00 | 6.00 |
| Minority Interest | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Cashflow From Operations | 5.6% | -104 | -111 | -119 | -114 | -94.75 | -99.46 | -70.67 | -7.31 | -8.71 | 12.00 | 17.00 | -38.13 | -32.02 | -27.21 | -26.06 | -19.73 | -17.73 | -18.49 |
| Share Based Compensation | 3.3% | 43.00 | 41.00 | 40.00 | 37.00 | 35.00 | 31.00 | 26.00 | 22.00 | 17.00 | 13.00 | 11.00 | 8.00 | 6.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Cashflow From Investing | 14.6% | 259 | 226 | 90.00 | 56.00 | 101 | 81.00 | -16.81 | -47.96 | -316 | -355 | -381 | -322 | -111 | -125 | -53.85 | -80.31 | -109 | -64.31 |
| Cashflow From Financing | 199.5% | 6.00 | 2.00 | 2.00 | 3.00 | 4.00 | 5.00 | 8.00 | 8.00 | 335 | 332 | 541 | 538 | 210 | 236 | 29.00 | 41.00 | 60.00 | 21.00 |
SDGR Income Statement
2023-06-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 35,189 | $ 38,469 | $ 99,971 | $ 87,132 |
| Cost of revenues: | ||||
| Total cost of revenues | 21,379 | 21,335 | 40,468 | 42,015 |
| Gross profit | 13,810 | 17,134 | 59,503 | 45,117 |
| Operating expenses: | ||||
| Research and development | 42,705 | 31,123 | 83,446 | 58,945 |
| Sales and marketing | 9,022 | 7,428 | 18,167 | 14,099 |
| General and administrative | 23,216 | 22,056 | 49,524 | 44,189 |
| Total operating expenses | 74,943 | 60,607 | 151,137 | 117,233 |
| Loss from operations | (61,133) | (43,473) | (91,634) | (72,116) |
| Other income (expense): | ||||
| Gain on equity investments | 0 | 11,828 | 147,322 | 11,828 |
| Change in fair value | 40,654 | (15,700) | 76,391 | (21,864) |
| Other income (expense) | 4,326 | (308) | 7,263 | 31 |
| Total other income (expense) | 44,980 | (4,180) | 230,976 | (10,005) |
| (Loss) income before income taxes | (16,153) | (47,653) | 139,342 | (82,121) |
| Income tax (benefit) expense | (20,431) | 33 | 5,928 | 5 |
| Net income (loss) | $ 4,278 | $ (47,686) | $ 133,414 | $ (82,126) |
| Earnings Per Share [Abstract] | ||||
| Net income (loss) per share of common and limited common stockholders, basic (in USD per share) | $ 0.06 | $ (0.67) | $ 1.86 | $ (1.15) |
| Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic (in shares) | 71,642,722 | 71,161,892 | 71,555,395 | 71,106,470 |
| Net income (loss) per share of common and limited common stockholders, diluted (in USD per share) | $ 0.06 | $ (0.67) | $ 1.79 | $ (1.15) |
| Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: (in shares) | 75,064,323 | 71,161,892 | 74,499,672 | 71,106,470 |
| Software products and services | ||||
| Revenues: | ||||
| Total revenues | $ 29,352 | $ 30,011 | $ 61,565 | $ 63,092 |
| Cost of revenues: | ||||
| Total cost of revenues | 6,695 | 7,101 | 13,810 | 14,612 |
| Drug discovery | ||||
| Revenues: | ||||
| Total revenues | 5,837 | 8,458 | 38,406 | 24,040 |
| Cost of revenues: | ||||
| Total cost of revenues | $ 14,684 | $ 14,234 | $ 26,658 | $ 27,403 |
SDGR Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 285,963 | $ 90,474 |
| Restricted cash | 5,053 | 5,243 |
| Marketable securities | 262,710 | 360,613 |
| Accounts receivable, net of allowance for doubtful accounts of $250 and $125 | 9,652 | 55,953 |
| Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $100 | 14,585 | 13,137 |
| Prepaid expenses | 13,999 | 8,569 |
| Total current assets | 591,962 | 533,989 |
| Property and equipment, net | 20,353 | 14,244 |
| Equity investments | 106,404 | 25,683 |
| Goodwill | 4,791 | 4,791 |
| Intangible assets, net | 0 | 587 |
| Right of use assets | 112,984 | 105,982 |
| Other assets | 5,072 | 3,311 |
| Total assets | 841,566 | 688,587 |
| Current liabilities: | ||
| Accounts payable | 12,428 | 9,470 |
| Income taxes payable | 5,134 | 355 |
| Accrued payroll, taxes, and benefits | 21,328 | 24,882 |
| Deferred revenue | 46,674 | 57,931 |
| Lease liabilities | 13,921 | 11,006 |
| Other accrued liabilities | 7,317 | 5,166 |
| Total current liabilities | 106,802 | 108,810 |
| Deferred revenue, long-term | 15,620 | 25,598 |
| Lease liabilities, long-term | 107,319 | 105,485 |
| Other liabilities, long-term | 600 | 800 |
| Total liabilities | 230,341 | 240,693 |
| Commitments and contingencies (Note 5) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 0 | 0 |
| Additional paid-in capital | 856,913 | 828,700 |
| Accumulated deficit | (245,724) | (379,138) |
| Accumulated other comprehensive loss | (683) | (2,382) |
| Total stockholders' equity | 611,225 | 447,894 |
| Total liabilities and stockholders' equity | 841,566 | 688,587 |
| Common Stock | ||
| Stockholders' equity: | ||
| Common and Limited Stock | 627 | 622 |
| Limited common stock | ||
| Stockholders' equity: | ||
| Common and Limited Stock | $ 92 | $ 92 |
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.